Form 8-K · Current report
Regeneron Pharmaceuticals 8-K, filed Oct 30, 2026
- Filed
- CIK
- 0000872589
- Accession no.
- 0000872589-26-000032
Summary
Regeneron Pharmaceuticals reported third-quarter 2026 revenues of $5.1 billion, up 36% from a year earlier, with GAAP EPS of $18.45 and non-GAAP EPS of $20.07, and said it expanded its antibody collaboration with Sanofi through a $1.0 billion up-front payment plus up to $7.0 billion in future milestones. The company also reported that the FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva and that Dupixent, EYLEA HD, and Libtayo each posted record net sales.
Key points
- Third-quarter 2026 total revenues rose 36% to $5.1 billion, with GAAP net income per diluted share of $18.45 and non-GAAP net income per diluted share of $20.07.
- Dupixent global net sales, recorded by Sanofi, increased 35% to $6.5 billion; EYLEA HD U.S. net sales rose 62% to $699 million; Libtayo global net sales rose 51% to $550 million.
- The amended Sanofi collaboration adds multiple next-generation long-acting Regeneron-invented antibodies, with development and commercialization costs and any future global profits shared equally.
- Regeneron announced an agreement with BARDA to supply Inmazeb doses to the U.S. government annually from 2027 through 2031 for Ebola preparedness.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 30, 2026, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended September 30, 2026. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.